LY-3114062

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameLY-3114062

Drug Alias NameLY3114062LY-3114062

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionInterleukin-17 receptor A modulatorsTumor necrosis factor α modulators

TargetsTumor necrosis factor αInterleukin-17 receptor A

Therapy Area/IndicationsArthritis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBulgariaRomaniaGeorgia +[4]

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesEli Lilly And Company

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesEli Lilly And Company

Active IndicationsN/A

Inactive IndicationsArthritis

Other Information

ATC CodeN/A